Kurse werden geladen...
Prognose
Das durchschnittliche Kursziel der Analysten beträgt 5,34€(+206,90%). Der Median liegt bei 5,34€(+206,90%).
Kaufen | 2 |
Halten | 1 |
Verkaufen | 0 |
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
News
Inotiv, Inc. (NOTV) Q2 2025 Earnings Call Transcript
Call Start: 16:30 January 1, 0000 5:20 PM ET Inotiv, Inc. (NASDAQ:NOTV ) Q2 2025 Earnings Conference Call May 7, 2025, 04:30 PM ET Company Participants Steve Halper - Investor Relations Bob Leasure - President and Chief Executive Officer Beth Taylor - Chief Financial Officer John Sagartz - Chief Strategy Officer Conference Call Participants Matt Hewitt - Craig-Hallum Capital Group Nelson Cox - Lake Street Capital Markets Dave Windley - Jefferies Operator Good day, everyone, and welcome to today's Inotiv Second Quarter Fiscal 2025 Earnings Call. [Operator Instructions] Please note, today's call will be recorded and I will be standing by should you need any assistance.» Mehr auf seekingalpha.com
Inotiv, Inc. (NOTV) Reports Q2 Loss, Tops Revenue Estimates
Inotiv, Inc. (NOTV) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.29 per share a year ago.» Mehr auf zacks.com
Inotiv Reports Second Quarter Financial Results for Fiscal 2025 and Provides Business Update
— Second quarter fiscal 2025 revenue increased 4.4% to $124.3 million— Year-to-date fiscal 2025 revenue declined 4.1% to $244.2 million— Conference call scheduled for today at 4:30 pm ET WEST LAFAYETTE, Ind., May 07, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months (“Q2 FY 2025”) ended March 31, 2025 and six months ("YTD FY 2025") ended March 31, 2025.» Mehr auf globenewswire.com
Unternehmenszahlen
(EUR) | Dez. 2024 | |
---|---|---|
Umsatz | 115,20 Mio | 6,01% |
Bruttoeinkommen | 24,06 Mio | 38,37% |
Nettoeinkommen | −26,55 Mio | 90,75% |
EBITDA | −1,72 Mio | 122,55% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 59,06 Mio€ |
Anzahl Aktien | 33,87 Mio |
52 Wochen-Hoch/Tief | 5,76€ - 1,02€ |
Dividenden | Nein |
Beta | 4,06 |
KGV (PE Ratio) | −0,44 |
KGWV (PEG Ratio) | 0,00 |
KBV (PB Ratio) | 0,31 |
KUV (PS Ratio) | 0,14 |
Unternehmensprofil
Name | Bioanalyticial Systems |
CEO | Robert W. Leasure Jr. |
Sitz | West Lafayette, in USA |
Mitarbeiter | 1.977 |
Ticker Symbole
Börse | Symbol |
---|---|
NASDAQ | NOTV |
Assets entdecken
Shareholder von Bioanalyticial Systems investieren auch in folgende Assets